North Bud Farms Inc. is focused on sustainable, low-cost cannabis production for pharmaceutical development and infused products. It has acquired a late-stage ACMPR applicant with a facility in Quebec. The company is well-positioned for legalization of infused products in 2019. It has an experienced team and plans to use proceeds from a convertible note raise to expand operations and research for consumer products. North Bud aims to be a major low-cost supplier in the growing cannabis market.

1. January 15, 2019
CSE: NBUD

2. 2
Forward Looking Statements
This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results
could differ materially from the expectations and projections of North Bud Farms Inc. The information contained in this presentation has not
been approved or disapproved by any Securities Commission in Canada, the Securities and Exchange Commission in the US or other
regulatory body. Except for statements of historical fact relating to the Company, certain information contained herein constitutes
"forward-looking statements".
Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and
other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other
factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These factors
include the inherent risks involved in making investments in the cannabis industry and associated ancillary businesses regulated by Canadian
federal and provincial governmental agencies, American federal and state governmental agencies or other international regulatory agencies,
the uncertainties involved in the cannabis industry and complexities and timelines associated with product or service approvals in multiple
jurisdictions.
The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing
needed in the future and other factors. Circumstances or management's estimates or opinions could change. The reader is cautioned not to
place undue reliance on forward-looking statements. Except as required by law, we undertake no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are
made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty,
express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation.
Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person
resulting from the use of the information in this presentation by you or any of your representatives or from omissions from the information in
this presentation.

3. 3
Mission
NORTHBUD will focus on sustainable low cost, high quality
cannabinoid production for unique clients focused on both
bio-pharmaceutical development and Cannabinoid Infused
Products (CIP)

4. 4
NORTHBUD at a Glance
NORTHBUD Founded 2017
CSE (NBUD) (As at January 14, 2019) CAD$0.285
Market Capitalization CAD$16M
Common Shares - Issued & Outstanding 55.5M
Common Shares - Fully Diluted 69M
Insider ownership 33%
G&A Burn Rate/ Month ~CAD$50K

5. Canadian regulatory door for CIP is opening in 2019.
As shown in other legal jurisdictions (Colorado, Washington, Nevada,
California) the infused products sector has become the highest margin
segment of the industry.
NORTHBUD is positioned to be a raw input producer for this space. Currently
working with multiple food, beverage and science companies to provide safe
standardized cannabinoid infused raw inputs for large scale GMP
manufacturing of products.
5
Cannabinoid Infused Products (CIP): Legalization 2.0

6. North Bud Farms Inc. has acquired late stage ACMPR applicant GrowPros
MMP from Tetra Bio-Pharma (TSXV: TBP).
GrowPros MMP application was submitted in November 2014 and is
currently in the ‘Confirmation of Readiness’ stage.
Phase 1 is located on 95 acres of agricultural farmland in Low, Québec.
The option exists to acquire more land if needed.
Facility will focus on GMP pharma-grade cultivation and food-grade
extracted inputs.
Significant opportunity potential with near term catalysts soon to be
completed.
6
The Investment Opportunity

7. 7
Positioned for Legalization 2.0
First mover advantage often becomes first-mover disadvantage
Examples: AOL, Netscape, Yahoo, BlackBerry
Second mover advantage: clearer picture of market and competition
Examples: Google, Facebook, Amazon, Apple, NORTHBUD

8. Edward Miller
VP, Investor Relations
17 years experience
Biotech/Pharma and
cannabis industries
Corporate branding
and investor
outreach for
Tetra-Bio Pharma,
bringing them public
Past-President QC
Chapter-Canadian
Investor Relations
Institute
Brad Stewart
Branding & IT
14 years experience in
brand, marketing,
digital, advertising,
sales, PR
Wine industry sales,
marketing, logistics,
supply-chain
experience
Digital/social media
pioneer and information
architect, published
writer, video producer,
photographer
Over 18 years of
cannabis industry
cultivation
Acute, sought after
expertise in large scale
cannabis production
Experience working with
multiple LPs
International network of
horticulturalists
professionals
8
Talented Team
Brendan Stutt
CFO
Chartered
Professional
Accountant (CPA,
CA)
Graduate of Queen's
University and McGill
University
10+ years of
experience as
corporate controller
for multiple publicly
traded companies
Ryan Brown
CEO & Board
Co-Founder & CEO of
North Bud Capital
Holdings. Co-Founder
of Tetra Bio-Pharma
Extensive experience in
hydroponic gardening
equipment sector
Early investor in
multiple ACMPR
producers and ancillary
companies
Steve Abboud
Chief Cultivation

9. André Audet
President & Chairman of
the Board
President of North Bud
Capital Holdings
Co-founder & past
chairman of Tetra
Bio-Pharma board of
directors
Held CEO & Director
positions for multiple
publicly listed companies
Over 25 years of financing
public companies
Leona Aglukkaq
Board
Member of Parliament,
Nunavut (2008-2015)
Government of
Canada, Minister of
Health (2008 -2013)
Government of
Canada, Minister of the
Environment (2013 -
2015)
Chair of Arctic Council
(2013-2015)
CEO, SXN Strategy
Partners
Former executive at
Altria and Philip Morris
Int’l, leading business
units on 3 continents
Investment committee
member at Trolley
Ventures
Board member on 2
private companies
Michael Saxon
Board
9
Experienced Board
Teresa DeLuca, MD, MBA
Board
New York Board-certified
in psychopharmacology
Clinical professor of
Psychiatry, Mt. Sinai
College, NY
Chief Medical Officer,
Magellan
VP, Clinical Sales
Walgreen Co.
Ryan Brown
CEO & Board
Co-Founder & CEO of
North Bud Capital
Holdings. Co-Founder
of Tetra Bio-Pharma
Extensive experience in
hydroponic gardening
equipment sector
Early investor in
multiple ACMPR
producers and ancillary
companies

10. Farm
Municipality of Low Québec
10 km from Paugan Dam
10
Head Office
Chelsea, Québec
Located 10 minutes north of Ottawa
Location

11. Phase 1: 25,000 Sq. Ft. (Construction begun)
Phase 2: 500,000 Sq. Ft. (Expected Q2, 2020)
Paugan Dam
10 km from site
2nd largest generating
capacity of dams in
Outaouais
Lowest cost per kWh in
Canada
11
95 Acres of Company - Owned Land
Site Details - Low Cost Infrastructure
10 km from Hydroelectric Infrastructure

12. Pharma Development
NORTHBUD will focus on GMP standardized production
We will focus on securing unique strains containing high amounts of specific
cannabinoids not typically found in recreational cannabis.
12
Strategic Verticals
Food Grade Inputs
Using our licensed encapsulation technology we will
engage existing food and beverage companies looking
to develop product lines containing cannabis.

13. Phase 1: Build out of 25,000 sq. ft. facility with 7,400 sq. ft. of cultivation space
During phase 1 of development NORTHBUD will be restricted to cultivation only.
Based on our allocated flowering space we estimate ~200g/sq. ft. of annualized
production in year one. We will spend this time developing our unique genetics and
perfecting our GMP cultivation process.
Projected annual production prior to obtaining a sales licence: 800 kg
Phase 2: 500,000 sq. ft. of outdoor cultivation in Q2, 2020
Projected annual production post phase 2 expansion: 12,000,000 grams
per year
Prospective revenue: $12M CDN per annum, assuming $1,000 per kg (current
price avg is $4,500 per kg 13
Revenue Projections

14. 14
Capital Structure Shares Round Cash
Shares: Founders Round 10,000,000 $0.05 $500,000
Private Placement #1 11,000,000 $0.10 $1,100,000
Private Placement #2 1,500,000 $0.10 $150,000
Tetra Bio-Pharma (dividend to
shareholders) 15,550,000 $0.20 Assets
Land Co. Purchase 760,000 $0.25 Assets
Private Placement #3 16,736,000 $0.25 $4,184,000
Outstanding
Shares: 55,546,000 Non Diluted Cash In $5,934,000
Warrants (Private Placement #3) 8,368,000 $0.40 $3,347,200
Options 5,150,000 $0.25 $1,287,500
Fully Diluted
Shares:
69,064,000 Fully Diluted Cash In $10,568,700

15. Phase I - 25,000 sq.ft. Facility Buildout:
15
Use of Proceeds
Low Production Facility $4,200,000
Operation Costs $600,000
Total $ 4.8M

16. Late Stage Applicants Market Cap
Cannara ~196 Million*
AgraFlora Organics (Prev. PUF Ventures) ~$111 Million*
MYM Nutraceuticals ~$66 Million*
Rose LifeScience Partners ~$63 Million**
LGC Capital ~$44 Million*
Liberty Leaf Holdings ~$17 Million*
NORTHBUD ~$16 Million*
*https://web.tmxmoney.com – January 14, 2019
**Rose LifeScience Partners is a private company
valued as at January 9, 2019
16
Comparables
$NBUD $LIB $LG.V $RLSP $MYM $AGRA $LOVE

17. Experienced & Strong Corporate Team & Board of Directors
● Public Company Executives: Extensive capital markets experience
● Chief Cultivation Officer: Recognized as a large-scale cannabis cultivation
expert among ACMPR Licensed Producers
Scalable Expansion Potential & Stable Business Model
● 95 acres of company-owned agricultural farmland in Low, Québec
● Unlimited electrical supply at the lowest rate per kWh in Canada, low-cost
labour & municipal taxes with available government subsidies
17
Investment Merits

18. ● Via a Convertible Note:
○ Raise CAD$2-2.5M
○ 9% yearly interest
○ Convertible at a discount of 20% to market
○ Forced exercise at $0.50
● Use of Funds:
○ Increase staffing
○ CPG R&D
○ Promotion and Marketing
18
Investment Opportunity – Current Ask

19. Edward Miller Ryan Brown
VP, Investor Relations CEO
+1(855) 628-3420 ext. 3 +1(613) 983-6995
edward@northbud.com ryan@northbud.com
19
Contacts